Harrow, Inc. (HROW)
46.77
+2.25
(+5.05%)
USD |
NASDAQ |
Dec 04, 16:00
46.80
+0.03
(+0.06%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.732B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 22.82% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.984 |
| Price to Book Value | 36.84 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 5.357 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 71.15% |
Profile
| Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN. |
| URL | http://www.harrow.com |
| Investor Relations URL | https://investors.harrow.com/ |
| HQ State/Province | Tennessee |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 10, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN. |
| URL | http://www.harrow.com |
| Investor Relations URL | https://investors.harrow.com/ |
| HQ State/Province | Tennessee |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Nov. 10, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |